

Our Case No. 10466/76

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)
Ashkenazi et al.	) )
Serial No. 09/904,992	) Examiner To be assigned
Filing Date: July 12, 2001	) Group Art Unit No. 1653
For SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME	) ) )

## STATEMENT ACCORDING TO 37 C.F.R. § 1.821(f)

#### **BOX SEQUENCE LISTING**

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Submitted herewith is a copy of the sequence listing in computer readable form. Applicants' representative states that the content of the attached compact disc copy in computer readable form of the Sequence Listing, submitted in accordance with 37 CFR 1.821(c) and (e), respectively, are identical.

Respectfully submitted,

Gregory M. Zinkl, Ph.D. Registration No. 48,492 Agent for Applicant

BRINKS HOFER GILSON & LIONE P.O. BOX 10395 CHICAGO, ILLINOIS 60610 (312) 321-4200

	TRANSMITTAL LETTER		TRANSMITTAL LETTER		Case No. 10466/76
W7 & 199 lal No.	Filing Date July 12, 2001	Examiner To be assigned	Group Art Unit		
Inventor(s) Ashkenazi et al.			<u> </u>		
Title of Invention SECRETED AND TRAN	SMEMBRANE POLYPEPTIDES AI	ND NUCLEIC ACIDS ENCODING	THE SAME		

			TO THE CO	OMMISSIONER F	OR PATENTS				
	e form; copy of I	Notice to C	a Statement Acc comply with Requi	rements for Pate	R. § 1.821(f); ont Applications (	copy of Se Containing I	guenc Nuclea	e <u>Listing in o</u> otide Sequend	computer ce_and/or
	Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously submitted.								
	A verified state	ement to es	stablish small entit	y status under 3	7 CFR §§ 1.9 and	d 1.27 is er	nclose	d.	
	A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.  Petition for a month extension of time.								
$\boxtimes$	No additional fo								
		·	ed as shown belov	***					
	The ree has be	en calculat	ed as shown below	w.				Other	Than
	<del></del>	1	Т.		Small	Entity	ח	Small Entity	
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Rate	Add'I Fee	or	Rate	Add'I Fee
Total		Minus			x \$9=			x \$18=	
Indep.		Minus			x 42=			x \$84=	
First Pre	esentation of Mul	tiple Dep. C	Claim		+ \$140 =			+ \$280=	
					Total add'I fee	\$		Total add'I fee	\$
	Please charge duplicate copy		ecount No. 23-19 et is enclosed.	25 (BRINKS HO	FER GILSON & I	LIONE) in t	he am	nount of \$	, A
	A check in the amount of \$ to cover the filing fee is enclosed.								
The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communication or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.									
I hereby petition under 37 CFR § 1.136(a) for any extension of time required to ensure that this paper is timely filed. Please charge any associated fees which have not otherwise been paid to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.									
Respectfully submitted,  Gregory M. Zinkl, Ph.D.  Registration No. 48,492									
Agent for Applicant BRINKS HOFER GILSON & LIONE P.O. BOX 10395 CHICAGO, ILLINOIS 60610 (312) 321-4200									
I hereby certify that this correspondence is being deposited with the United States Postal Service as express mail, label no. EL 562415094US, with sufficient postage, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on									
Date: Olize OV Signature: ###									
rev. Dec0	oo •		_						



## United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE Washington, DIG 2023 www.usdig.gov

APPLICATION NUMBER	FILING RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09 904,992	07 ב 17 2001	Avi Ashkenazi	P1618P2C30

Paul E. Rauch, Ph.D Brinks, Hofer, Gilson & Lione NBC Tower - Suite 3600 455 Cityfront Plaza Drive Chicago, IL 60611-5599



CONFIRMATION NO. 8661

FORMALITIES LETTER

\*OC0000000007128186\*

Date Mailed: 11/28/2001

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• A request to transfer the computer readable form from another application on file at the U.S. Patent and Trademark Office has been submitted as permitted by 37 C.F.R. 1.821(e). However, the request cannot be complied with since there is no compliant CRF present at the United States Patent and Trademark Office. Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE